CriticalAntidepressants. Other antidepressants of herbal origin×Triptan, selective 5HT1B/1D receptor agonist
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Zolmitriptan is a selective serotonin 5-HT1 receptor agonist (zolmitriptan SmPC, AEMPS, section 5.1). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with triptans, including zolmitriptan (St John's wort SmPC, AEMPS, section 4.5). The zolmitriptan SmPC also states that adverse reactions may be more frequent when triptans are used with St John's wort preparations (zolmitriptan SmPC, AEMPS, section 4.5). Zolmitriptan metabolism depends on CYP1A2 (zolmitriptan SmPC, AEMPS, section 5.2). The St John's wort SmPC lists CYP1A2 among the enzymes that St John's wort induces (St John's wort SmPC, AEMPS, section 4.5). The documents do not describe how St John's wort changes zolmitriptan levels.
Symptoms
The St John's wort summary of product characteristics (SmPC) warns of increased serotonergic effects and more frequent adverse reactions when St John's wort is combined with triptans (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The Spanish zolmitriptan SmPC describes serotonin syndrome as potentially life-threatening. The diagnosis is likely when a person taking a serotonergic medicine has one of the following: spontaneous clonus, inducible ocular clonus with agitation and diaphoresis, tremor and hyperreflexia, or hypertonia with body temperature above 38 °C and inducible ocular clonus (zolmitriptan SmPC, AEMPS, section 4.4). Serotonin syndrome may occur with triptans, including zolmitriptan, particularly with selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants and monoamine oxidase (MAO) inhibitors (zolmitriptan label, US Food and Drug Administration, FDA, section 5.7). St John's wort is not on this list. According to this label, signs include agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting and diarrhoea. They usually appear within minutes to hours of a new or higher dose of a serotonergic medicine (FDA zolmitriptan label, section 5.7).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with medicines of the triptan group, and its interaction table names zolmitriptan (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The zolmitriptan documents are less strict. The Spanish zolmitriptan SmPC states that adverse reactions may be more frequent with St John's wort preparations but does not prohibit the combination (zolmitriptan SmPC, AEMPS, section 4.5). The zolmitriptan label of the US Food and Drug Administration (FDA) does not mention St John's wort. If the two have nevertheless been taken together and serotonin syndrome is suspected, stop zolmitriptan (FDA zolmitriptan label, section 5.7). After serotonergic medicines are stopped, the condition improves quickly, and treatment depends on the nature and severity of the symptoms (zolmitriptan SmPC, AEMPS, section 4.4). No document says how long to wait between stopping St John's wort and taking zolmitriptan.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Zolmitriptán, Zomig 2,5 mg (nº registro 61826), sección 4.5 (2022)– AEMPS, CIMA, nº registro 61826, revisión 05/2022, secciones 4.2 y 4.5
- FDA: Zomig (zolmitriptan) prescribing information (2024)– FDA, DailyMed, setid 1d977430-f494-415d-9daf-3c3163156249, Amneal Pharmaceuticals, revisión 02/2024, secciones 4, 5.7 y 7.2
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA